6
Oct
2022

Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Enveda Cashes In, Otsuka Hits ALS Goal, & Viking Braces for GLP-1 Battle
Scholar Rock Gets FDA OK, Reverse Mergers Continue & Novartis Bets on Brain Delivery
Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On
Alumis & BioNTech Stumble, Lilly Buys Merida, & Takeda’s Latest FDA Approval